-
Article
Open AccessCardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
Patients with HER2-positive metastatic breast cancer (MBC) usually receive many years of trastuzumab treatment. It is unknown whether these patients require continuous left ventricular ejection fraction (LVEF)...
-
Article
Open AccessImpact of Second Opinions in Breast Cancer Diagnostics and Treatment: A Retrospective Analysis
Breast cancer care is becoming increasingly complex, and patients with breast cancer are increasingly aware of the different treatment options, resulting in requests for second opinions (SOs). The current stud...
-
Article
Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?
Patients with HER2-positive metastatic breast cancer (MBC) treated with trastuzumab may experience durable tumor response for many years. It is unknown if patients with durable radiological complete remission ...
-
Article
Open AccessThe impact of health symptoms on health-related quality of life in early-stage breast cancer survivors
In breast cancer patients, treatment-related health symptoms can occur that may affect their health-related quality of life (HRQoL). This study aimed to determine the impact of health symptoms on HRQoL in brea...
-
Article
Open AccessRandomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer
Preclinical research and prior clinical observations demonstrated reduced toxicity and suggested enhanced efficacy of cisplatin due to folic acid and vitamin B12 suppletion. In this randomized phase 2 trial, w...
-
Article
Open AccessCYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
Breast cancer patients with absent or reduced CYP2D6 activity and consequently low endoxifen levels may benefit less from tamoxifen treatment. CYP2D6 poor and intermediate metabolizers may need a personalized ...
-
Article
Erratum to: The use of the 13C-dextromethorphan breath test for phenoty** CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels
-
Article
The use of the 13C-dextromethorphan breath test for phenoty** CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels
Adjuvant therapy with tamoxifen significantly reduces breast cancer recurrence and mortality in estrogen receptor positive disease. CYP2D6 is the main enzyme involved in the activation of the prodrug tamoxifen...
-
Article
Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane
A phase II study was performed to investigate the efficacy and tolerability of gemcitabine as third-line chemotherapy for patients with metastatic breast cancer, previously treated with both an anthracycline -...
-
Chapter
New Chemotherapeutic Agents: A Selection of Some of the Most Promising New Drugs
The past decade has seen few active new agents emerging from the preclinical screening. However, now a large number of promising anticancer agents is being introduced into the clinic. There is no doubt that th...
